Hematopoietic Cell Therapy
Hematopoietic stem cells (HSCs) have long been used to provide life-saving treatments for patients with malignant and non-malignant hematological disorders. While these treatments originally took the form of conventional bone marrow transplants, more recent breakthroughs in the field have provided cell therapy researchers with methods to correct genetic mutations in a patient’s own cells for autologous HSC transplantation.
We have compiled a selection of scientific resources to help you on your way in the complex and exciting field of hematopoietic cell therapy.
Featured
CRISPR-Cas9 Editing of Hematopoietic Stem and Progenitor Cells
In this webinar, Dr. Mark DeWitt will discuss the use of gene editing techniques for hematopoietic stem and progenitor cells HSPCs. Topics he will include are:
- Delivery of gene editing machinery to target cells
- Homology-directed repair for precise editing
- Culture conditions required for efficient editing
- Levels of correction needed for the treatment of monogenic disorders, such as sickle cell disease
-
The CFU Assay: In Vitro Functional Potency Assessment for Hematopoietic Stem and Progenitor CellsThe colony-forming unit (CFU) assay remains the only in vitro assay that provides a correlative assessment of hematopoietic stem and progenitor cell (HSPC) engraftment potential in vivo. For many years, regulatory bodies have recommended functional assessment and the CFU assay for labs working with cellular therapies or transplantable products derived from HSPCs. Recent updates from regulatory bodies such as FACT underscore the crucial role of the CFU assay in these workflows, particularly after any processing step, such as cryopreservation, that may impact the functional properties of HSPC products. <br><br> In this webinar, Selena Hallahan introduces the utility of the CFU assay for functional assessment of hematopoietic cell products and º£½ÇÆƽâ°æ Technologies’ comprehensive portfolio of reagents, training, and services designed to support high-performing and standardized workflows for hematopoietic cell therapy products. -
Serum-Free Expansion of CD34+ Cells with SFEM II and UM729Explore the use of StemSpanâ„¢ SFEM II medium, StemSpanâ„¢ CD34+ Expansion Supplement and small molecules UM171 or UM729 to enhance expansion of HSPCs -
David Knapp, PhDDr. David Knapp shares his work examining how growth factors affect the survival, proliferation, and maintenance of cells of the cord blood HSC compartment -
Maturation of Culture-Expanded Erythroid Progenitor CellsTechnical tip from our dedicated team of Product and Scientific Support specialists -
Hematopoietic Stem Cell Fitness and Function During Sickle Cell DiseaseChronic insults, such as inflammation and replicative stress, impair and exhaust blood-sustaining hematopoietic stem cells (HSCs), leading to dysfunction and selection for leukemia-associated mutations. Dr. McKinney-Freeman’s laboratory is currently studying how sickle cell disease (SCD), an inherited hemolytic anemia with a large inflammatory component and increased hematopoietic demand, compromises the fidelity and function of hematopoietic stem cells (HSCs) in both mice and individuals with SCD. Mounting evidence indicates that SCD patients may experience enhanced rates of clonal hematopoiesis, as well as MDS (myelodysplastic syndrome) and AML (acute myeloid leukemia), in general, and following allogeneic HSC transplantation or autologous HSC gene therapy. Considering that these are the only curative therapies for SCD, it is important to better understand and prevent SCD-induced insults to HSCs and their microenvironment. <br><br> In this webinar, Dr. McKinney-Freeman from St. Jude Children’s Research Hospital describes, in detail, what her laboratory has learned about how SCD affects HSCs. Additionally, Dr. McKinney-Freeman is joined by Dr. Eric Norris, Account Executive, Cell Culture, º£½ÇÆƽâ°æ Technologies in the Q&A session. -
Frequently Asked Questions on Primary CellsTechnical tip from our dedicated team of Product and Scientific Support specialists -
Evaluating Hematopoietic Cell Therapy Product Potency Using the CFU AssayTechnical tip from our dedicated team of Product and Scientific Support specialists
